OpenLegislation

The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013

S.I. 2013/349 · Made 14 February 2013 · Extends to United Kingdom

Not fully up to date. 2 changes made by later legislation have not yet been written into this text, which is revised to 1 October 2026.

See the changes not yet applied
ProvisionChangeMade by
Sch. 4 para. 28(2)(e)(ia)insertedNational Health Service (Pharmaceutical and Local Pharmaceutical Services) 2026 reg. 10(4)
Sch. 7 para. 12(3)insertedNational Health Service (Pharmaceutical and Local Pharmaceutical Services) 2026 reg. 11(3)

National Health Service, England

Made 14th February 2013

Laid before Parliament 22nd February 2013

Coming into force 1st April 2013

The Secretary of State makes the following Regulations in exercise of the powers conferred by sections 7, 8, 126, 128A, 129, 130, 132, 136, 139, 140, 142(b), 143, 145, 148, 150A, 151(5) and (7), 154, 159(9), 160, 161, 162, 163(3), 164, 169(3) and 272(7) and (8) of, and paragraph 1(2)(b) of Schedule 11 and paragraphs 2 and 3 of Schedule 12 to, the National Health Service Act 2006 M1.

Annotations to the whole text

Marginal citations

M1

2006 c.41. Section 7 has been amended by the Health and Social Care Act 2012 (c. 7) (“the 2012 Act”), section 21(1) to (4); section 8 has been amended by the 2012 Act, Schedule 4, paragraph 5; section 126 has been amended by the 2012 Act, sections 213(7)(k) and 220(7), and Schedule 4, paragraph 63; section 128A was inserted by the Health Act 2009 (c.21), section 25, and amended by the 2012 Act, section 206(1); section 129 has been amended by the Health Act 2009, sections 26 and 27 and Schedule 6, by the 2012 Act, section 207(1) to (9), and Schedule 4, paragraph 66, by the Protection of Freedoms Act 2012 (c. 9), Schedule 9, paragraph 121, and by S.I. 2010/231; section 130 has been amended by the 2012 Act, section 207(10), and by S.I. 2010/22; section 132 has been amended by the 2012 Act, Schedule 4, paragraph 69, by the Protection of Freedoms Act 2012, Schedule 9, paragraph 122, and by S.I. 2007/289 and 2010/22 and 231; section 136 has been amended by the 2012 Act, section 207(11), and Schedule 4, paragraph 72; section 140 has been amended by the 2012 Act, Schedule 4, paragraph 75; section 148 has been amended by the 2012 Act, Schedule 4, paragraph 77, and by S.I. 2010/22; section 150A was inserted by the Health Act 2009, section 28, and amended by the 2012 Act, Schedule 4, paragraph 78; section 151 has been amended by the 2012 Act, Schedule 4, paragraph 80; section 154 has been amended by the 2012 Act, Schedule 4, paragraph 81, and by S.I. 2010/22; section 160 has been amended by the 2012 Act, Schedule 4, paragraph 86; section 161 has been amended by the 2012 Act, Schedule 4, paragraph 87; section 162 has been amended by the 2012 Act, Schedule 4, paragraph 88; section 164 has been amended by the Health and Social Care Act 2008 (c. 14), section 141(1), and Schedule 15, Part 4, and by the 2012 Act, Schedule 4, paragraph 89; section 169 has been amended by S.I. 2010/22; paragraph 2 of Schedule 12 has been amended by the Health Act 2009, section 29(12), and by the 2012 Act, section 207(12), and Schedule 4, paragraph 93(3); paragraph 3 of Schedule 12 has been amended by the Health Act 2009, section 29(13) to (15), and by the 2012 Act, Schedule 4, paragraph 93(4). By virtue of section 271(1) of the 2006 Act, the functions of the Secretary of State being exercised in the making of these Regulations are exercisable only in relation to England. See also section 275(1) of the 2006 Act, which contains definitions of “prescribed” and “regulations” that are relevant to the powers being exercised.

Contents

  1. Part 1: Introductory
  2. 1Citation and commencement
  3. 2Interpretation
  4. Part 2: Pharmaceutical needs assessments
  5. 3Pharmaceutical needs assessments
  6. 4Information to be contained in pharmaceutical needs assessments
  7. 5Date by which the first HWB pharmaceutical needs assessments are to be published
  8. 6Subsequent assessments and later first assessments
  9. 7Temporary extension of earlier pharmaceutical needs assessments and access by NHS England and HWBs to pharmaceutical needs assessments
  10. 8Consultation on pharmaceutical needs assessments
  11. 9Matters for consideration when making assessments
  12. Part 3: General matters relating to pharmaceutical lists and applications in respect of them
  13. 10Pharmaceutical lists ...
  14. 11Terms of service of NHS chemists: general
  15. 12Routine applications for inclusion in or amendments to a pharmaceutical list
  16. 13Current needs: additional matters to which NHS England must have regard
  17. 14Current needs: consequences of additional matters
  18. 15Future needs: additional matters to which NHS England must have regard
  19. 16Future needs: consequences of additional matters
  20. 17Improvements or better access to the current service: additional matters to which NHS England must have regard
  21. 18Unforeseen benefits applications: additional matters to which NHS England must have regard
  22. 19Applications to which regulation 17 or 18 applies: consequences of additional matters
  23. 20Future improvements or better access: additional matters to which NHS England must have regard
  24. 21Future improvements or better access: consequences of additional matters
  25. 21APNA based applications for new premises offering additional or different opening hours
  26. 22Refusal of routine applications that are based on neither a pharmaceutical needs assessment nor unforeseen benefits
  27. Part 4: Excepted applications
  28. 23Applications from NHS chemists in respect of providing directed services
  29. 24Relocations that do not result in significant change to pharmaceutical services provision
  30. 25Distance selling premises applications
  31. 25ATransitional provision: distance selling premises applications for new inclusions made before 23rd June 2025
  32. 26Change of ownership applications
  33. 26AConsolidation onto an existing site
  34. 27Applications for temporary listings arising out of suspensions
  35. 28Applications from persons exercising a right of return to a pharmaceutical list
  36. 29Temporary arrangements during emergencies or because of circumstances beyond the control of NHS chemists
  37. Part 5: Specific grounds for refusal or deferral of applications under Parts 3 and 4 which are not linked to fitness grounds
  38. 30Refusal: language requirement for some NHS pharmacists
  39. 31Refusal: same or adjacent premises
  40. 32Deferrals arising out of LPS designations
  41. Part 6: Refusal, deferral and conditional inclusion in pharmaceutical lists of chemists on fitness grounds
  42. 33Refusal of applications for inclusion in a pharmaceutical list on fitness grounds
  43. 34Deferral of consideration of applications for inclusion in a pharmaceutical list on fitness grounds
  44. 35Granting applications for inclusion in a pharmaceutical list subject to efficiency conditions and conditions to combat fraud
  45. Part 7: Areas that are controlled localities or reserved locations, and new pharmacies within them
  46. 36Determination that an area is a controlled locality
  47. 37Process for determining controlled localities: preliminary matters
  48. 38Process for determining controlled localities: local notification and deferment of routine applications
  49. 39Process of determining controlled localities: formulation of NHS England’s decision
  50. 40Applications for new pharmacy premises in controlled localities: refusals because of preliminary matters
  51. 41Applications for new pharmacy premises in controlled localities: reserved locations
  52. 42Second and subsequent determinations of reserved location status
  53. 43Determinations of reserved locations: supplemental matters
  54. 44Prejudice test in respect of routine applications for new pharmacy premises in a part of a controlled locality that is not a reserved location
  55. 45Appeals against decisions under Part 7
  56. Part 8: Dispensing doctors
  57. 46Dispensing doctor lists
  58. 47Terms of service of dispensing doctors: general
  59. 48Arrangements for the provision of pharmaceutical services by doctors: applications by patients
  60. 49Necessary services for temporary patients
  61. 50Discontinuation of arrangements for the provision of pharmaceutical services by doctors
  62. 51Outline consent and premises approval: applications by doctors
  63. 52Notification of applications for outline consent and premises approval
  64. 53Decisions on outline consent and premises approval applications and the taking effect of grants
  65. 54Premises approval: relocations of practice premises which are not significant before outline consent takes effect
  66. 55Premises approval: relocations of practice premises which are not significant after outline consent has taken effect
  67. 56Taking effect of premises approval where there is no related application for outline consent
  68. 57Gradual introduction of premises approval
  69. 58Temporary provision in cases of relocations or additional premises where premises approval has not taken effect
  70. 59Practice amalgamations
  71. 60Lapse of outline consent and premises approval
  72. 61Temporary arrangements during emergencies or circumstances beyond the control of a dispensing doctor
  73. 62Persons barred from taking part in decision making with regard to applications for outline consent or premises approval
  74. 63Appeals against decisions under Part 8
  75. Part 9: Conditional inclusion in pharmaceutical lists: certain specific conditions that do not relate to fitness or performance
  76. 64Distance selling premises: specific conditions
  77. 65Core opening hours conditions
  78. 65AContinuity in respect of opening hours directions
  79. 66Conditions relating to providing directed services
  80. 66AConditions relating to independent prescribing
  81. 67Conditions relating to voluntary closure of premises
  82. 67ACondition relating to entering administration
  83. 68Conditions relating to local resolution of disputes over terms of service
  84. Part 10: Performance related sanctions and market exit
  85. 69Local dispute resolution before serving remedial notices or breach notices
  86. 70Breaches of terms of service: remedial notices
  87. 71Breaches of terms of service: breach notices
  88. 71AIssuing breach or remedial notices while a disease is or in anticipation of a disease being imminently pandemic etc.
  89. 72Payment withholdings: supplementary matters
  90. 73Removal of listings: cases relating to remedial notices and breach notices
  91. 74Removal of listings: cases relating to death, incapacity or cessation of service
  92. 75Voluntary and automatic removal of listings: change of ownership, relocation, temporary provision and voluntary closure
  93. 76Limitation on withdrawal from pharmaceutical lists while fitness investigations or proceedings are ongoing
  94. 77Appeals against decisions under Part 10
  95. Part 11: Enforcement, reviews and appeals relating to fitness matters
  96. 78Extended meaning of “health scheme” in fraud cases
  97. 79Review of decisions to impose fitness conditions originally imposed on grants of applications
  98. 80Removal for breach of fitness conditions imposed under regulation 35 or 79
  99. 81Mandatory removal in suitability cases
  100. 82Fitness cases: procedures for removal or contingent removal from pharmaceutical lists
  101. 83Procedure for suspensions in fitness cases
  102. 84Procedure for reviewing some suspensions and contingent removal conditions
  103. 85General power to revoke suspensions in appropriate circumstances
  104. 86Internal handling of fitness information by NHS England or an agent of NHS England
  105. 87Review periods for national disqualifications
  106. 88Wider notifications of fitness decisions
  107. Part 12: Remuneration, charges and refunds
  108. 89The Drug Tariff and section 164: general provisions
  109. 90Data to be provided to assist Drug Tariff determinations
  110. 91Remuneration of NHS chemists: instruments of appointment of NHS England
  111. 91AZero or nominal product reimbursement for ... vaccines and antivirals
  112. 92Dispensing doctor remuneration
  113. 93The taking effect of determinations
  114. 94Overpayments
  115. 95Free supply of drugs, appliances and containers where the drug or appliance is supplied under pharmaceutical services
  116. 96Refunds of prescription charges
  117. 97Reward scheme
  118. 98Payments to suspended chemists
  119. Part 13: Local Pharmaceutical Services
  120. 99Designation of areas, premises or descriptions of premises
  121. 100Review of designations
  122. 101Cancellation of designations
  123. 102Terms of service for LPS schemes: general
  124. 102ASuspension of terms of schemes or of enforcement of terms of schemes while a disease is or in anticipation of a disease being imminently pandemic etc.
  125. 103LPS schemes: health service body status
  126. 104Development of LPS schemes
  127. 105Persons permitted to be parties to LPS schemes: fitness criteria
  128. 106LPS proposals: fitness information to be supplied
  129. 107Notification of proposals
  130. 108Right of return to pharmaceutical lists: LPS contractors
  131. 109LPS pilot schemes: health service body status
  132. 110LPS pilot schemes: termination
  133. 111Emergencies requiring the flexible provision of local pharmaceutical services
  134. 112Sharing of information about LPS chemists and their employees with the General Pharmaceutical Council
  135. 113Directions to the First-tier Tribunal relating to local pharmaceutical services
  136. 114Lists of LPS chemists
  137. Part 14: Miscellaneous
  138. 115Notification by NHS England of changes to its lists
  139. 116Authorised persons to apply for services
  140. 117Functions of the Secretary of State to be exercised by the NHS Litigation Authority
  141. 118Proceedings relating to overridden arrangements
  142. 119Transitional provisions
  143. 119ATransitional provisions in respect of drugs or appliances supplied in accordance with SSPs
  144. 120Amendments and revocations
  145. 121Review of these Regulations
  146. Signature
  147. Schedule 1: Information to be contained in pharmaceutical needs assessments
  148. 1Necessary services: current provision
  149. 2Necessary services: gaps in provision
  150. 3Other relevant services: current provision
  151. 4Improvements and better access: gaps in provision
  152. 5Other NHS services
  153. 6How the assessment was carried out
  154. 7Map of provision
  155. Schedule 2: Applications in respect of pharmaceutical lists and the procedures to be followed
  156. Part 1: Information to be included in routine and excepted applications
  157. 1Information to be included in all routine and excepted applications
  158. 2Information to be included in all routine and excepted applications for inclusion in a pharmaceutical list
  159. 3Fitness information about individuals: routine and excepted applications for inclusion in a pharmaceutical list
  160. 4Fitness information about corporate bodies: routine and excepted applications for inclusion in a pharmaceutical list
  161. 5Fitness information that has already been provided under pharmaceutical or local pharmaceutical services
  162. 5AUpdating of information about or relating to a superintendent
  163. 6Applications seeking the listing of premises that are already, or are in close proximity to, listed chemist premises
  164. 7Additional information to be included with routine applications
  165. 8Additional information to be included with excepted applications
  166. 9Undertakings
  167. 10Nature of details to be supplied
  168. Part 2: Preliminary matters
  169. 11Relevant information or documentation
  170. 12Failure to provide undertakings or fees
  171. 13Functions of NHS England in relation to fitness information relevant to applications: aggregation of information
  172. 14Deferral of notifiable applications prior to notification
  173. 15Refusal of notifiable applications prior to notification because of the language requirement for some NHS pharmacists
  174. 16Refusal of notifiable applications on fitness grounds prior to notification
  175. 17Proposed new pharmacy premises in controlled localities: refusal of routine applications because of preliminary matters prior to notification
  176. Part 3: Notification of certain applications
  177. 18Applications requiring notifications
  178. 19Notification procedure for notifiable applications
  179. 20Parallel notifications
  180. 21Content of notifications
  181. Part 4: Determination and deferral of applications
  182. 22Flexibility with regard to determining or deferring applications
  183. 23Additional matters for consideration in relation to applications for inclusion in a pharmaceutical list
  184. 24Action following deferrals
  185. 25Oral hearings
  186. 26Persons barred from taking part in decision making on routine and excepted applications
  187. 27Timetable for determining applications
  188. Part 5: Notification, taking effect of decisions and rights of appeal to the Secretary of State
  189. 28Notification of decisions on routine and excepted applications
  190. 29Template notice of commencement to be included with a notice of decision
  191. 29ATemplate notice of consolidation
  192. 30Third party rights of appeal to the Secretary of State where an application is granted
  193. 31Conditional grant of applications where the address of the premises is unknown
  194. 32Changes to the premises specified in an application after its grant but before the listing of the premises
  195. 33Conditional grant in cases relating to future needs or future improvements or better access
  196. 34Taking effect of listing decisions: general
  197. 34ATaking effect of decisions relating to business consolidations
  198. 35Notice requiring the commencement of pharmaceutical services
  199. 36Appeals to the Secretary of State by the applicant
  200. Schedule 3: Appeals to the Secretary of State
  201. Part 1: Preliminary matters
  202. 1Determination of third party appeal rights in certain cases
  203. 2Misconceived appeals
  204. Part 2: Notification of appeals
  205. 3Notification of appeals notices under paragraph 30, 32(5) or 36 of Schedule 2
  206. 4Notification of appeals relating to notices under regulation 45
  207. 5Notification of appeals relating to decisions under Part 8 of these Regulations
  208. 6Non notification of appeals relating to notices under regulation 77 or 98
  209. Part 3: Determination of appeals
  210. 7Flexibility with regard to the manner of determining appeals
  211. 8Oral hearings
  212. 9Decisions of the Secretary of State
  213. 10Notification of decisions and subsequent action by NHS England
  214. 11Effect of decisions by the Secretary of State
  215. Schedule 4: NHS England’sTerms of service of NHS pharmacists
  216. Part 1: General
  217. 1Responsibilities of NHS pharmacists and pharmacy staff
  218. 2Breaches by directors and superintendents
  219. Part 2: Essential services
  220. 3Essential services
  221. 4Dispensing services
  222. 5Dispensing of drugs and appliances
  223. 5ASupply in accordance with a SSP
  224. 5BSupply in accordance with a PTP or a PTPGD
  225. 5CSupply in accordance with a LPIV
  226. 6Urgent supply without a prescription
  227. 7Preliminary matters before providing ordered drugs or appliances
  228. 7ASub-contracting aspects of dispensing under “hub and spoke” arrangements
  229. 7BObjection to and discontinuation of hub and spoke arrangements
  230. 7CHub and spoke arrangements: sharing of “relevant data” between different businesses
  231. 8Providing ordered drugs or appliances
  232. 9Refusal to provide drugs or appliances ordered
  233. 10Further activities to be carried out in connection with the provision of dispensing services
  234. 11Additional requirements in relation to electronic prescribing
  235. 12Additional requirements in relation to specified appliances
  236. 13Disposal service in respect of unwanted drugs
  237. 14Basic procedure in respect of unwanted drugs
  238. 15Further activities to be carried out in connection with the disposal of unwanted drugs
  239. 16Promotion of healthy lifestyles
  240. 17Prescription linked intervention
  241. 18... Health campaigns
  242. 19Signposting
  243. 20Service outline in respect of signposting
  244. 21Support for self-care
  245. 22Service outline in respect of support for self-care
  246. 22AHome delivery service while a disease is or in anticipation of a disease being imminently pandemic etc.
  247. 22AAHome delivery of notified items while a disease is or in anticipation of a disease being imminently pandemic etc.
  248. 22BDischarge medicines service
  249. 22CService outline in respect of the discharge medicines service
  250. Part 3: Hours of opening
  251. 23Pharmacy opening hours: general
  252. 23ALocal hours plans
  253. 23BClosure for learning and development
  254. 24Matters to be considered when issuing directions in respect of pharmacy premises core opening hours
  255. 25Determination of pharmacy premises core opening hours instigated by NHS England
  256. 26Determination of pharmacy premises core opening hours instigated by the NHS pharmacist
  257. 27Temporary opening hours and closures during an emergency requiring the flexible provision of pharmaceutical services
  258. 27APharmacy opening hours: arrangements while a disease is or in anticipation of a disease being imminently pandemic etc.
  259. 27BFlexible provision of relevant immunisation services during a pandemic etc.
  260. Part 4: Other terms of service
  261. 28Clinical governance and the promotion of healthy living
  262. 28APremises requirements in respect of consultation rooms
  263. 28BConsultations held from distance selling premises and some small pharmacy premises
  264. 28CDistance selling premises requirements in respect of websites and health promotion zones
  265. 29Professional Standards
  266. 29AAccessing summary care records
  267. 29BElectronic Prescription Service access
  268. 29CContact via NHS.net Connect, pharmacy profiles and the Central Alerting System
  269. 29DBusiness continuity plans to deal with temporary suspensions
  270. 30Inducements etc.
  271. 31Duty to provide information about fitness matters as they arise
  272. 32Other information to be supplied
  273. 32AFacilitating remote access to pharmaceutical services
  274. 33Co-operation with NHS England
  275. 34Complaints
  276. 35Inspections and access to information
  277. Schedule 5: Terms of service of NHS appliance contractors
  278. 1Division of responsibilities between individuals and corporate bodies
  279. 2Breaches by directors
  280. 3Dispensing services
  281. 4Dispensing of appliances
  282. 4ASupply in accordance with a SSP
  283. 5Urgent supply without a prescription
  284. 6Preliminary matters before providing appliances
  285. 7Providing appliances
  286. 8Refusal to provide appliances ordered
  287. 9Further activities to be carried out in connection with the provision of dispensing services
  288. 10Additional requirements in relation to electronic prescribing
  289. 11Additional requirements in relation to specified appliances
  290. 12Signposting
  291. 13Opening hours: general
  292. 14Matters to be considered when issuing directions in respect of core opening hours
  293. 15Determination of core opening hours instigated by NHS England
  294. 16Determination of core opening hours instigated by the NHS appliance contractor
  295. 17Temporary open hours and closures during an emergency requiring the flexible provision of pharmaceutical services
  296. 18Clinical governance
  297. 19Professional Standards
  298. 20Inducements etc.
  299. 21Duty to provide information about fitness matters as they arise
  300. 22Other information to be supplied
  301. 23Co-operation with NHS England
  302. 24Complaints
  303. 25Inspections and access to information
  304. Schedule 6: Terms of service of dispensing doctors
  305. 1Persons duly authorised to dispense on behalf of dispensing doctors
  306. 2Dispensing of drugs and appliances ordered by another prescriber
  307. 3Dispensing of drugs and appliances ordered by the dispensing doctor
  308. 3ASupply in accordance with a SSP
  309. 3BSupply in accordance with a PTP or a PTPGD
  310. 3CSupply in accordance with a LPIV
  311. 4Preliminary matters before providing ordered drugs or appliances
  312. 4ZASub-contracting aspects of dispensing under “hub and spoke” arrangements
  313. 4ZBObjection to and termination of hub and spoke arrangements
  314. 4ZCHub and spoke arrangements: sharing of “relevant data” between different businesses
  315. 4ACharge exemption and remission of charges: declarations and checks
  316. 4BChecks and records in the case of supply in accordance with a SSP
  317. 5Provision of Scheduled drugs
  318. 6Refusal to provide drugs or appliances ordered
  319. 7Dispensing doctors issuing prescription forms which may be presented to an NHS chemist
  320. 7AHome delivery service while a disease is or in anticipation of a disease being imminently pandemic etc.
  321. 7AAHome delivery of notified items while a disease is or in anticipation of a disease being imminently pandemic etc.
  322. 8Complaints procedures
  323. 9Inspections and access to information
  324. 10Voluntary closure of premises
  325. Schedule 7: Mandatory terms for LPS schemes
  326. 1General provisions
  327. 2Restrictions in an LPS scheme on supply
  328. 3Dispensing
  329. 3ASupply in accordance with a SSP
  330. 3BSupply in accordance with a LPIV
  331. 4Urgent supply without a prescription
  332. 5Preliminary matters before providing ordered drugs or appliances
  333. 5ASub-contracting aspects of dispensing under “hub and spoke” arrangements
  334. 5BObjection to and discontinuation of hub and spoke arrangements
  335. 5CHub and spoke arrangements: sharing of “relevant data” between different businesses
  336. 6Providing ordered drugs or appliances
  337. 7Refusal to provide drugs or appliances ordered
  338. 8Further activities to be carried out in connection with the provision of dispensing services
  339. 9Additional requirements in relation to electronic prescribing
  340. 10Further activities in connection with repeat dispensing
  341. 10AHome delivery service while a disease is or in anticipation of a disease being imminently pandemic etc.
  342. 10AAHome delivery of notified items while a disease is or in anticipation of a disease being imminently pandemic etc.
  343. 11Information to be provided for NHS England’s lists
  344. 12Clinical governance
  345. 13Professional Standards
  346. 13AAccessing summary care records
  347. 13BElectronic Prescription Service access
  348. 13CContact via NHS.net Connect and the Central Alerting System
  349. 14Inducements etc
  350. 15Duty to provide information about fitness to practise matters as they arise
  351. 16Co-operation with NHS England
  352. 17Charges for drugs, appliances and containers, and ownership of containers
  353. 18Refunds of prescription charges
  354. 19Remuneration, overpayments etc
  355. 20Local resolution of disputes
  356. 21Dispute resolution: non-NHS contracts
  357. 22NHS dispute resolution procedure
  358. 23Determination of dispute
  359. 24Disputes: supplemental
  360. 25Complaints
  361. 26Variation of LPS schemes
  362. 27Termination by agreement
  363. 28Termination by serving notice
  364. 29Termination of arrangements by NHS England on grounds of suitability etc
  365. 30Termination by NHS England: patient safety and material financial loss
  366. 31Termination and the NHS dispute resolution procedure
  367. 32Third party rights
  368. Schedule 8: Service remuneration determined by NHS England
  369. 1Paragraph 1
  370. 2Paragraph 2
  371. Schedule 9: Transitional provisions
  372. 1The continuity principles
  373. 2Listing applications under the 2005 Regulations: NHS chemists
  374. 3Listing applications under the 2012 Regulations: NHS chemists
  375. 4Listing applications under the 2005 Regulations: dispensing doctors
  376. 5Listing applications under the 2012 Regulations: dispensing doctors
  377. 6Outstanding cases relating to dispensing contractor lists
  378. 7Controlled localities
  379. 8Reserved locations
  380. 9Gradual discontinuation of the provision of pharmaceutical services by doctors
  381. 10Gradual introduction of the provision of pharmaceutical services by doctors
  382. 11Giving effect to listing decisions: pharmaceutical lists and dispensing doctor lists
  383. 12Pharmaceutical lists, EPS lists and dispensing doctor lists: continuity of entries and decisions
  384. 13Service provision issues: NHS chemists
  385. 14Service provision issues: dispensing doctors
  386. 15LPS schemes: replacement of Primary Care Trusts with NHS England and service provision issues
  387. 16Notification of LPS designations and completion of reviews
  388. 17The application of Group 12 of Schedule 8 to the Value Added Tax Act 1994
  389. Schedule 10: Amendments and revocations
  390. 1Amendment of the National Health Service (Charges for Drugs and Appliances) Regulations 2000 Repealed
  391. 2Revocation of the National Health Service (Local Pharmaceutical Services and Pharmaceutical Services) Regulations 2002
  392. 3Revocation of the National Health Service (Local Pharmaceutical Services and Pharmaceutical Services) (No. 2) Regulations 2002
  393. 4Revocation of the National Health Service (Pharmaceutical Services) Amendment Regulations 2005
  394. 5Revocation of the National Health Service (Local Pharmaceutical Services etc.) Regulations 2006 and amendments to those Regulations
  395. 6Revocation of the National Health Service (Pharmaceutical Services) (Amendment) Regulations 2006
  396. 7Amendments to the Local Authority Social Services and National Health Service Complaints (England) Regulations 2009
  397. 8Revocation of the National Health Service (Pharmaceutical Services and Local Pharmaceutical Services) Amendment Regulations 2009
  398. 9Revocation of the National Health Service (Pharmaceutical Services and Local Pharmaceutical Services) (Amendment) Regulations 2010
  399. 10Revocation of the National Health Service (Local Pharmaceutical Services) Amendment Regulations 2012
  400. 11Revocation of the National Health Service (Pharmaceutical Services) Regulations 2012 and of amendments to those Regulations
  401. 12Amendment of the Local Authorities (Partnership Arrangements, Care Trusts, Public Health and Local Healthwatch Arrangements etc.) Regulations 2012
  402. Explanatory note